Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818256 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
A Phase 2 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT03818256 is a Phase 2 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 71 participants.
The verdict
NCT03818256, a Phase 2 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications.
Interventions
- DRUG Placebo
- DRUG Miricorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818256
The ClinicalTrials.gov registry entry for NCT03818256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03818256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818256 about?
NCT03818256 is a clinical study titled "A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications". This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications.
What is the current status of trial NCT03818256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2019-12-04. Estimated completion is 2022-07-06.
What interventions are being tested in trial NCT03818256?
The interventions under investigation include: Placebo (DRUG), Miricorilant (DRUG).
Who is sponsoring clinical trial NCT03818256?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.